YOLFTbeta
Aclaris Therapeutics Inc

Aclaris Therapeutics Inc

ACRS · NASDAQ · Healthcare / Biotechnology

3.92USD-0.08 (-2.00%)

Price History

Full chart

Market Stats

Previous Close4.00
Open3.98
Day Range3.78 – 3.99
52-Week Range1.74 – 6.60
Volume1.15M
Market Cap791.93M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.58
Dividend Yield0.00%
Beta0.80
50-Day Avg5.78
200-Day Avg4.39

About

Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Neal S. Walker D.O., M.D.
  • Employees69
  • Headquarters701 Lee Road, Wayne, PA, United States, 19087, USA
  • Websitehttps://www.aclaristx.com

Leadership

  • Dr. Neal S. Walker D.O., M.D.Co-Founder, CEO & Chairman · b. 1970
  • Dr. Hugh M. Davis Ph.D.President, COO & Director · b. 1960
  • Mr. Kevin BalthaserChief Financial Officer · b. 1987
  • Mr. James LoeropChief Business Officer · b. 1965
  • Dr. Roland Kolbeck Ph.D.Chief Scientific Officer · b. 1964
  • Mr. William C. RobertsSenior Vice President of Corporate Communications & Investor Relations · b. 1969
  • Mr. Matthew Rothman J.D.General Counsel & Corporate Secretary
  • Mr. Steve TuckerExecutive Vice President of Project Leadership
  • Dr. Jesse W. Hall M.D.Chief Medical Officer · b. 1974
  • Ms. Nina Samra M.S.Senior Vice President of Clinical Operations

Financials

Income Statement

Currency: USD2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue-0001.68M10.09M4.23M6.48M6.76M29.75M31.25M18.72M7.83M
Growth (%)-----+499.58%-58.11%+53.35%+4.30%+340.05%+5.03%-40.09%-58.19%
Cost of Revenue-090.00K120.00K1.21M6.85M4.05M5.13M4.71M11.96M18.08M2.79M2.09M
Gross Profit-0-90.00K-120.00K476.00K3.24M172.00K1.35M2.05M17.79M13.17M15.93M5.74M
Gross Margin----28.28%32.12%4.07%20.81%30.29%59.80%42.14%85.09%73.28%
Operating Expense-8.53M20.58M48.45M72.90M138.66M111.23M52.26M91.77M107.65M110.53M157.86M82.11M
Operating Income-5.26M-8.53M-20.67M-48.57M-72.42M-135.41M-111.06M-50.91M-89.72M-89.85M-97.36M-141.93M-76.38M
Operating Margin-----4303.21%-1341.93%-2627.35%-785.44%-1327.07%-302.01%-311.55%-758.18%-975.91%
EBITDA-5.25M-8.52M-20.58M-48.45M-72.02M-133.53M-90.23M-49.59M-64.46M-84.36M-115.45M-51.72M-64.47M
EBITDA Margin-----4279.32%-1323.31%-2134.71%-765.01%-953.42%-283.53%-369.46%-276.28%-823.78%
Net Income-5.24M-8.52M-20.56M-48.08M-68.52M-132.74M-161.35M-51.15M-90.86M-86.91M-88.48M-132.06M-64.92M
Net Income Margin-----4071.48%-1315.41%-3817.22%-789.17%-1343.96%-292.11%-283.15%-705.48%-829.58%
R&D3.49M6.51M15.34M33.48M39.79M63.01M64.90M31.73M43.81M77.81M98.38M33.59M52.65M
R&D as % of Total Revenue----2364.23%624.41%1535.34%489.52%648.03%261.54%314.84%179.41%672.69%
Interest Expense00000001.04M23.42M4.70M---
Interest Expense % of Total Revenue----0.00%0.00%0.00%16.03%346.34%15.80%---

Balance Sheet

Currency: USD2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets14.21M17.38M94.08M176.09M243.51M275.57M98.30M70.78M251.21M254.60M197.41M220.33M160.46M
Total Liabilities23.37M38.13M1.55M6.59M18.25M60.44M28.39M33.13M53.87M56.98M40.23M64.77M57.38M
Total Equity-9.16M-20.75M92.52M169.49M225.26M215.12M69.91M37.65M197.34M197.62M157.18M155.55M103.08M
Cash9.59M10.76M9.85M30.17M208.85M57.02M35.94M22.06M27.35M45.28M39.88M24.57M19.96M
Total Debt----142.00K30.52M658.00K11.26M693.00K684.00K426.00K2.60M2.12M
Net Debt-9.59M-10.76M-9.85M-30.17M-208.71M-26.50M-35.30M-10.81M-26.66M-44.59M-39.45M-24.57M-17.84M

Cash Flow

Currency: USD2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-4.92M-7.64M-20.37M-34.60M-54.66M-100.81M-96.44M-38.63M-52.13M-67.57M-78.33M-20.07M-47.11M
Investing Cash Flow-4.54M-1.78M-76.95M-61.90M-55.69M9.37M105.68M6.39M-167.63M12.63M46.22M-69.77M48.37M
Financing Cash Flow-10.58M96.41M116.83M100.39M128.26M-30.32M18.37M225.05M72.87M26.71M74.54M-5.86M
Capital Expenditure0417.00K507.00K232.00K1.24M1.36M1.61M453.00K308.00K605.00K1.31M121.00K111.00K
Free Cash Flow-4.92M-8.05M-20.88M-34.84M-55.90M-102.17M-98.06M-39.09M-52.44M-68.17M-79.63M-20.20M-47.11M
Dividends Paid--000--7.74M3.12M----
FCF to OCF100.00%105.46%102.49%100.67%102.26%101.35%101.67%101.17%100.59%100.90%101.67%100.60%100.00%
Dividend Paid to FCF--0.00%0.00%0.00%---19.79%-5.96%----

Earnings

Report DateNov 18, 2015Mar 23, 2016May 11, 2016Aug 11, 2016Nov 3, 2016Mar 15, 2017May 9, 2017Aug 8, 2017Nov 7, 2017Mar 12, 2018May 8, 2018Aug 3, 2018Nov 6, 2018Mar 18, 2019May 8, 2019Aug 8, 2019Nov 7, 2019Feb 25, 2020May 7, 2020Aug 7, 2020Nov 4, 2020Feb 25, 2021May 7, 2021Aug 5, 2021Nov 2, 2021Feb 24, 2022May 10, 2022Aug 3, 2022Nov 8, 2022Feb 23, 2023May 8, 2023Aug 7, 2023Nov 6, 2023Feb 27, 2024May 7, 2024Aug 7, 2024Nov 6, 2024Feb 25, 2025May 8, 2025Aug 7, 2025Nov 6, 2025Feb 26, 2026May 7, 2026Aug 6, 2026Nov 5, 2026
EPS Estimate-3.04-0.28-0.48-0.59-0.66-0.59-0.56-0.68-0.82-0.86-1.00-1.00-1.12-0.99-0.76-0.72-0.69-0.32-0.32-0.33-0.28-0.27-0.28-0.28-0.28-0.36-0.41-0.36-0.40-0.45-0.44-0.45-0.49-0.39-0.29-0.20-0.01-0.38-0.12-0.13-0.14-0.15-0.16-0.16-0.16
EPS Actual-5.11-0.28-0.65-0.62-0.50-0.49-0.48-0.56-0.63-0.80-0.98-1.01-1.06-0.99-0.91-1.21-0.56-0.46-0.37-0.28-0.25-0.30-0.57-0.34-0.35-0.37-0.31-0.31-0.30-0.41-0.42-0.42-0.41-0.02-0.24-0.15-0.11-1.01-0.12-0.13-0.12-0.16-0.15-0.15-
Surprise-68.09%0.00%-35.42%-5.08%24.24%16.95%14.29%17.65%23.17%6.98%2.00%-1.00%5.36%0.00%-19.74%-68.06%18.84%-43.75%-15.63%15.15%10.71%-11.11%-103.57%-21.43%-25.00%-2.78%24.39%13.89%25.00%8.89%4.55%6.67%16.33%94.87%17.24%25.00%-1000.00%-169.33%0.00%0.00%14.29%-6.67%6.25%6.25%-
TimingAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketAfter-hoursPre-marketAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-market-Pre-marketPre-marketPre-market

Key Statistics & Ratios

Market Cap791.93M
Enterprise Value681.97M
Trailing P/E0.00
Forward P/E0.00
PEG Ratio-0.13
Price / Sales96.35
Price / Book6.21
EPS-0.58
Book Value0.891
Revenue (TTM)8.22M
Gross Profit (TTM)-62.27M
EBITDA-85.53M
Profit Margin0.00%
Operating Margin-1469.49%
Return on Equity-59.10%
Return on Assets-28.98%
Shares Outstanding147.20M
Shares Float101.17M
Beta0.80
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Buy
Based on 6 analystsTarget 10.18
  • Strong Buy
    3
  • Buy
    2
  • Hold
    1

Ownership Breakdown

Institutions
84.01%
Insiders
2.18%
Retail / Other
13.81%

Top Institutional Holders

  • BML Capital Management LLC
    11.97M8.14%
  • Deep Track Capital, LP
    9.35M6.35%
  • BlackRock Inc
    7.41M5.03%
  • RA Capital Management, LLC
    6.80M4.62%
  • Vivo Capital, LLC
    6.69M4.55%
  • Vanguard Capital Management, LLC
    5.17M3.51%
  • Frazier Life Sciences Management, L.P.
    4.93M3.35%
  • Rock Springs Capital Management LP
    4.33M2.94%
  • Adage Capital Partners Gp LLC
    4.07M2.77%
  • Decheng Capital LLC
    4.04M2.75%
  • Balyasny Asset Management LLC
    3.36M2.28%
  • Kalehua Capital Management LLC
    3.17M2.15%
  • Morgan Stanley - Brokerage Accounts
    2.75M1.87%
  • Geode Capital Management, LLC
    2.42M1.65%
  • State Street Corp
    2.01M1.36%
  • Citadel Advisors Llc
    1.76M1.20%
  • Jones Hill Capital LP
    1.76M1.20%
  • BRAIDWELL LP
    1.70M1.15%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    4.24M2.88%
  • iShares Russell 2000 ETF
    3.05M2.07%